Product Details

CAT No.# CS-CM-00060
Category Metabolites
CAS 55224-05-0
Molecular Weight 759.92
Molecular Formula C38H65NO14
Synonyms: (3aR,4R,7R,8S,9S,13R,15R,15aR)-10-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-4-ethyl-11-hydroxy-8-(((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-3a,7,9,11,13,15-hexamethyloctahydro-3aH-[1,3]dioxolo[4,5-c][1]oxacyclotetradecine-2,6,14(4H,7H)-trione
Application Notes: Davercin (erythromycin A cyclic 11,12-carbonate) is a first generation semi-synthetic erythromycin. Davercin is prepared by coupling the 11- and 12-OH groups to form a cyclic carbonate. This simple modification improves the stability and hydrophobicity of the macrocyclic structure. Davercin shows comparable or better in vitro potency, low host toxicity and improved pharmacokinetics compared with erythromycin.L-aspartate of erythromycin A cyclic 11,12-carbonate, a new semisynthetic erythromycin derivative.
COA / MSDS:    View COA    MSDS    Enquire
The balance used are calibrated with weights traceable to National Standards NIST for accuracy
PEOPLE ALSO SEARCHED FOR: 1. (6R,7S)-7-(2-chloroacetamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
2. 3-bromo-2,2-dimethyl-butane
3. propan-2-yl-5-hydroxy-2-methyl-2-4-(3-nitrophenyl)-6-oxo-1,4,5,5-tetraahydropyridine-3-carboxylate
4. ([13C6]Leu5)-Ghrelin (human) (H-7252.1000)
5. Benidipine D7
6. Lauroside D
7. Triazolam 13C D3
8. Icatibant impurity 1
10. 0.1% TFA in Water ULC-MS
11. Metamizole EP Impurity C HCl
12. Silodosin Metabolite D4
13. Brivaracetam Carboxylic acid metabolite [UCB 42145]
14. Terbuthylazine D5
15. tibolone (848)
16. (Z)-Dimethylvinphos
17. Silodosin Metabolite
18. 2-Phenoxymethanesulfonanilide
19. Nimesulide EP Impurity A
20. Acetone HPLC

This page contains information about Davercin Cas 55224-05-0 and its Metabolites.
"Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk."